CLOZAPINE + RISPERIDONE vs PLACEBO + CLOZAPINE
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
1 finding from 1 review
- 1.13 [0.53, 2.42]3 studies · 167 participantsVery low
Findings
What do systematic reviews say?
4 questions · 4 findings · 3 reviews
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 2 · 50%Low 1 · 25%Moderate 1 · 25%High 0 · 0%
CHLORPROMAZINE vs QUETIAPINE
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
CHLORPROMAZINE showed no clear difference in leaving the study early due to any reason short term (up to 6 months) compared with QUETIAPINE (moderate certainty).
1 finding from 1 review
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes onlyRR 1.04 [0.77, 1.41]12 studies · 1223 participantsModerate
CHLORPROMAZINE vs OLANZAPINE
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
It is very uncertain whether CHLORPROMAZINE changes leaving the study early due to any reason: short term (up to 6 months) compared with OLANZAPINE (very low certainty).
1 finding from 1 review
- Chlorpromazine versus atypical antipsychotic drugs for schizophrenia 2016 · Cochrane Headline outcomes onlyRR 1.69 [0.45, 6.4]3 studies · 139 participantsVery low
HALOPERIDOL vs first‐generation antipsychotics
Behaviour: Leaving the study early (short‐term) · patients with schizophrenia
Haloperidol showed no clear difference in leaving the study early due to any reason as a measure of overall… compared with first‐generation antipsychotics (low certainty).
1 finding from 1 review
- Haloperidol versus first‐generation antipsychotics for the treatment of schizophrenia and other psychotic disorders 2015 · Cochrane Headline outcomes onlyRR 1.04 [0.87, 1.24]28 studies · 1299 participantsLow